Choosing between hims and Sprout for weight loss involves weighing full platform capabilities and clinical depth against a lower entry price. hims operates as an established multi-category telehealth leader serving over 2 million members since 2017, providing GLP-1 medications through board-certified obesity medicine physicians with digital health technology and integration across erectile dysfunction, hair loss, and mental health services. Sprout is a weight loss specialist offering compounded semaglutide from $149/month and compounded tirzepatide from $199/month, verified September 17, 2026, with streamlined clinical support and no published price for higher doses. This comparison analyzes treatment options, pricing differences, clinical support quality, platform technology, and service scope to help you decide which approach fits your goals, budget and healthcare priorities.
Platform Overview
hims launched in 2017 as one of the pioneering direct-to-consumer telehealth platforms, expanding to serve over 2 million customers across weight loss, erectile dysfunction, hair loss, mental health, and premature ejaculation. The platform operates through a network of board-certified healthcare providers offering FDA-approved medications and evidence-based treatments with digital health tools. hims has established itself as a mainstream telehealth leader with significant venture capital backing, public market listing, and proven track record serving patients in all 50 states.
Sprout is a weight loss telehealth platform specializing in GLP-1 medication access, with compounded semaglutide from $149/month and compounded tirzepatide from $199/month, verified September 17, 2026. We can't verify its founding date or operating history from our data, so we won't rank it on track record. The platform positions itself between ultra-budget providers and premium programs, offering both molecules with basic clinical support at competitive entry pricing, and it does not publish what a higher dose costs. Sprout focuses exclusively on weight loss treatment without additional health categories, aimed at you if you want reliable GLP-1 access through straightforward telemedicine consultations. The platform operates with a streamlined setup optimized for medication delivery efficiency.
Weight Loss Treatment Options
hims GLP-1 Program: hims provides full weight loss treatment through board-certified obesity medicine physicians, offering semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) as the FDA-approved branded products, with no compounded formulation on its weight loss page as of September 12, 2026. The platform follows evidence-based dosing protocols from the
American Association of Clinical Endocrinology, with medication management including dose escalation, side effect monitoring, and treatment adjustments based on individual response. hims integrates weight loss services within its broader multi-category telehealth platform, allowing coordination with mental health, metabolic, and other concurrent treatments when clinically relevant.
Sprout Medication Focus: Sprout specializes in compounded GLP-1 medications, providing semaglutide and tirzepatide formulations, and does not name the pharmacy that compounds them. The platform offers standard dosing escalation following established protocols but operates with a slimmed-down clinical model focused primarily on medication access rather than obesity treatment programming. Sprout provides basic medical consultations for prescription authorization and refill management but offers limited lifestyle intervention, behavioral support, or nutrition counseling beyond medication prescribing. The value-tier positioning emphasizes affordable medication delivery through efficient operations.
Clinical Efficacy: Both platforms provide access to GLP-1 medications with well-established weight loss efficacy. FDA Wegovy prescribing information reports average weight loss of 14.9% body weight over 68 weeks with semaglutide 2.4mg in the STEP 1 trial (2.4% with placebo; individual results vary).
FDA Zepbound label reports average weight loss of 15% to 20.9% depending on dose in the 72-week SURMOUNT-1 trial (individual results vary). The active medications are the same in each case (compounded versions are not FDA-approved, and individual results vary), though treatment success depends partially on clinical support quality, adherence monitoring, and side effect management - areas where platforms differ in service intensity.
Pricing and Value Comparison
hims Pricing Structure: hims prices brand-name medication directly: oral Wegovy $149/month, the Wegovy pen $199/month, Zepbound $299/month, with Ozempic and Mounjaro at $1,899/month. A Weight Loss Membership is required alongside it, $39 the first month and $149/month after, billed separately and excluding medication. Budget $298/month ongoing at the entry tier, roughly $3,576 a year, and note that the current structure carries no separate $49 consultation fee (checked September 12, 2026). hims is cash-pay for weight loss medication and accepts HSA/FSA.
Sprout Starting Prices: Sprout lists compounded semaglutide from $149/month and compounded tirzepatide from $199/month, verified September 17, 2026. Those are starting prices and Sprout publishes nothing about what a higher dose costs, so ask for your quoted rate after your evaluation. We have no sourced figure for a separate consultation fee either, so confirm the full monthly charge at checkout. Sprout operates as a cash-pay service without insurance billing. hims charges $149-299/month for medication alongside a separate $149/month membership, which takes its entry tier to $298/month, so both of Sprout's starting rates open below that.
Value Assessment: Sprout's $149 and $199 starting rates both land below hims' $298/month entry tier once the hims membership is counted, which makes Sprout worth a look if you are optimizing on price, provided you ask what your own dose will cost. However, hims provides clinical support, platform technology, and multi-category integration that may justify higher costs if you value those features.
Medical Team and Clinical Support
hims' Medical Network: hims operates with a network of board-certified physicians including obesity medicine specialists licensed across all 50 states. The platform employs providers with specific training in metabolic disease management and GLP-1 therapy. hims provides asynchronous telemedicine consultations with typical provider response times of 24-48 hours for clinical questions. The platform offers strong medication management including dose optimization, side effect monitoring and intervention, contraindication screening, and care coordination with primary care providers when appropriate. Patients have ongoing access to medical team for treatment adjustments and clinical guidance.
Sprout Streamlined Provider Network: Sprout operates with licensed healthcare providers offering basic telemedicine consultations focused on GLP-1 prescription authorization and refill management. The platform does not emphasize board certification in obesity medicine or metabolic training for its provider network. Clinical interactions primarily occur during initial consultation and refill requests, with limited ongoing clinical engagement beyond prescription management. Sprout's lighter model prioritizes efficiency and cost reduction over intensive clinical support, adequate for straightforward cases but with less medical oversight than established platforms.
Clinical Support Comparison: hims provides substantially more intensive medical supervision with experienced obesity medicine physicians, complete treatment protocols, and established systems for managing complications or complex medical situations. Sprout offers adequate basic prescribing services but lacks the clinical depth for patients with complicated medical histories, multiple medications, or those experiencing significant treatment challenges. JAMA research on telemedicine quality emphasizes the importance of qualified provider networks and comprehensive clinical support for chronic disease management, particularly for medications requiring ongoing monitoring like GLP-1 therapies. That deeper bench is a meaningful quality advantage if you want closer medical oversight.
Platform Features and User Experience
hims Platform Technology: hims offers telehealth platform technology including full-featured mobile applications for iOS and Android, secure provider messaging systems, automated prescription refill management, medication shipment tracking, and integrated health data tools. The platform provides educational resources about GLP-1 medications, side effect guidance, and weight tracking features. hims has invested substantially in user experience design, creating intuitive interfaces refined through years of user feedback. The platform integrates weight loss services with hims broader health offerings, enabling patients to manage multiple health concerns through unified account and coordinated provider network.
Sprout, Kept Simple: Sprout operates with straightforward platform technology focused on essential telemedicine functions - consultation questionnaires, prescription processing, medication ordering, and basic account management. The platform provides adequate functionality for medication access but lacks the sophisticated digital health features of more established competitors. Sprout does not offer native mobile applications, advanced health tracking tools, automated systems for refill management and adherence support. That simplicity aligns with Sprout's value-tier positioning, prioritizing cost efficiency over technological sophistication.
Technology Experience Gap: hims delivers significantly more refined user experience with mature platform capabilities including mobile accessibility, tracking tools, automated convenience features, and seamless integration across health categories. Sprout provides functional but basic technology adequate for medication ordering without the polish and feature richness of platforms with greater development investment. For patients who value digital health tools, mobile accessibility, and broad platform features, hims represents substantially more sophisticated option despite higher costs.
Treatment Scope and Service Integration
hims Multi-Category Platform: hims serves patients across weight loss, erectile dysfunction (sildenafil, tadalafil, PT-141), hair loss (finasteride, minoxidil, dutasteride, custom formulations), mental health (sertraline, escitalopram, bupropion for depression/anxiety), and premature ejaculation (sertraline, paroxetine). This breadth enables patients to address multiple interconnected health concerns through unified platform with coordinated clinical care. For patients with common comorbidities associated with obesity - including erectile dysfunction, depression, and metabolic syndrome - hims integrated approach provides management avoiding fragmented care across multiple providers and platforms. The wider medication formulary includes dozens of treatment options across these categories.
Sprout Single-Category Focus: Sprout exclusively provides weight loss medications without services for other health conditions. This narrow specialization allows focus and cost optimization for GLP-1 delivery but limits platform utility for patients with multiple health needs. Patients requiring treatment for conditions beyond weight loss must establish separate relationships with other telehealth providers or healthcare sources, managing multiple accounts, provider networks, and payment systems. Sprout does not offer the integrated care coordination possible with multi-category platforms treating interconnected conditions.
Service Breadth Implications: For patients needing exclusively weight loss medication, Sprout focused model may adequately serve their needs at lower cost. However, many weight loss patients have co-occurring conditions including erectile dysfunction, depression, sleep disorders, and metabolic dysfunction. hims ability to completely address these interconnected health issues through one platform with coordinated medical care provides significant convenience and potentially superior clinical outcomes compared to fragmented care across multiple providers - a meaningful advantage for patients with typical obesity-related comorbidities.
FDA-Approved Option Versus Compounded-Only
Hims lists the Wegovy pen at $199/mo and oral Wegovy at $149/mo before its $149/mo membership; Sprout starts compounded tirzepatide at $199/mo and compounded semaglutide at $149/mo, verified September 17, 2026. Hims is rated 9.4 Outstanding and Sprout 9.0 Excellent.
Sprout's own listing is compounded-only (compounded semaglutide and tirzepatide, shipped refrigerated from a US pharmacy); compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.
Hims' own listing, by contrast, features name-brand, FDA-approved GLP-1s alongside lower-cost oral choices, so where the medication line items match on paper the real question is whether having an FDA-approved option on the menu matters to you, and what each one bills you once membership and your actual dose are counted. Check which medication your prescription would be for before you enroll.
How We Compared Hims vs Sprout Health
Our Comparison Methodology
This comparison is based on analysis of treatment protocols, pricing structures, medical team qualifications, platform capabilities, and service scope from both hims and Sprout.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication labels including Wegovy (semaglutide) and Zepbound (tirzepatide). Information on medication efficacy, dosing protocols, and safety monitoring reflects established medical evidence for GLP-1 therapies in obesity management.
Pricing Analysis: Pricing reflects the rates last recorded in our provider database; providers change prices frequently, so confirm current pricing directly at checkout. Cost comparisons calculated for typical treatment courses providing accurate annual expense estimates for cash-pay patients across both semaglutide and tirzepatide formulations.
Service Verification: Platform capabilities, medical team credentials, medication formularies, service scope, and history evaluated through platform documentation, provider licensing verification, technology assessment, and company background research. Evaluation includes clinical support depth, technology sophistication, and company histories relevant to long-term treatment continuity.
Independence: This comparison is our own editorial work (most providers listed here pay ManyTreatments a commission when you buy through a link on this page; none pays for a placement, a rating, or a listing, and we make no claim that commissions have never influenced anything, since that is our own conduct and we cannot evidence it) and aims to provide evidence-based analysis helping patients select appropriate weight loss telehealth services based on clinical needs, budget considerations, and service preferences for chronic obesity management.
Final Verdict: Hims vs Sprout Health
Choose hims if: You value an established platform with 7+ years of history, public company transparency, and proven track record serving 2 million+ patients for long-term chronic disease management confidence. You want clinical support from board-certified obesity medicine specialists with strong medication management, side effect monitoring, and treatment optimization protocols. You appreciate advanced platform technology including native mobile apps, automated systems, tracking tools, and refined user experience from a mature digital health platform. You have or anticipate developing other health needs (erectile dysfunction, hair loss, mental health) that benefit from integrated multi-category care through coordinated provider network. You prioritize maximum clinical resources, platform sophistication, and certainty even at higher monthly costs ($199-399).
Choose Sprout if: You want the lower entry price, compounded semaglutide from $149/month or compounded tirzepatide from $199/month, verified September 17, 2026, both below hims' $298 entry tier once the hims membership is counted, and you are willing to ask what your own dose costs since Sprout does not publish that. You have a straightforward medical history without complications requiring intensive physician consultation or complex medication management. You need exclusively weight loss medication without other health services, and a single-category platform serves you adequately. You are comfortable with functional but basic platform technology without advanced digital health features or mobile applications.
Bottom line: hims and Sprout represent different positions on the cost-quality spectrum in weight loss telehealth - hims offers clinical infrastructure, a multi-year record, platform technology, and multi-category integration at premium pricing ($199-399/month), while Sprout provides medication access from $149/month for semaglutide and $199/month for tirzepatide with adequate basic clinical support for straightforward cases. If you have medical complexity, multiple health conditions, or you want maximum clinical resources and long-term certainty, hims' higher costs deliver real additional value through experienced obesity medicine physicians, strong support systems, proven platform stability, and integrated care. For a straightforward case where the monthly bill matters, Sprout's entry rates buy adequate clinical services and focused weight loss expertise, a middle ground between premium platforms and bare-bones budget services, with the caveat that its published figures are starting prices. We can't verify how long it has been operating, so weigh it on its verified prices and its 9.0 rating. The decision depends on whether you prioritize full support and maximum certainty (hims) or the cheaper way in (Sprout).
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
